跳转至内容
Merck
CN

HCMBMAG-22K

MILLIPLEX® 人癌症/转移生物标志物磁珠板 - 癌症多重检测

Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MILLIPLEX® 人癌症/转移生物标志物磁珠板 - 癌症多重检测, Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel

species reactivity

human

Quality Level

assay range

accuracy: 70-105%, standard curve range: 0,019-80 ng/mL
(TRAP5), standard curve range: 0,048-20 ng/mL
(YKL40), standard curve range: 0.002-10 ng/mL
(GDF15), standard curve range: 0.007-30 ng/mL
(DKK-1), standard curve range: 0.007-30 ng/mL
(OPG), standard curve range: 0.036-150 ng/mL
(NSE), standard curve range: 0.195-800 ng/mL
(Periostin), standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC)), inter-assay cv: <16%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum, plasma, tissue/cell culture supernatants or lysate samples.

Analytes included: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

通过在此面板中选择可用的分析物来设计多重试剂盒。

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib
R H Brophy et al.
Osteoarthritis and cartilage, 27(12), 1778-1789 (2019-08-21)
Emerging evidence suggests that injury to the anterior cruciate ligament (ACL) typically initiates biological changes that contribute to the development of osteoarthritis (OA). The molecular biomarkers or mediators of these biological events remain unknown. The goal of this exploratory study
Alison Crichton et al.
Journal of neurotrauma, 38(8), 1151-1163 (2019-12-28)
Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not predicted reliably persisting fatigue (up to three years post-injury). This

相关内容

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持